News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Change in the number of shares and votes in Egetis Therapeutics

May 31, 2022

Stockholm, Sweden, May 31, 2022. The number of shares and votes in Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (STO: EGTX) has increased in the month of May as a result of the guaranteed issue of shares with preferential rights (the “Rights Issue”). 
As a result of the Rights Issue the total number of shares and votes has increased by 49 520 568, to 214 589 128. The share capital has increased by SEK 2 606 347, to SEK 11 294 169.
The shares in the Rights Issue will be registered with the Swedish Companies Registration Office in June 2022.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10